

## 2011 Imaging Criteria

### Computed Tomography (CT), Brain<sup>(1)</sup>

ICD-9-CM: 87.03  
 CPT: 70450, 70460, 70470, 76380  
 I/O Setting: Outpatient

#### INDICATION(S)

- 100 Acute onset persistent neurologic Sx/findings (suspected stroke/CVA) ◆
  - 200 Follow-up study post stroke/CVA
  - 300 New transient neurologic Sx/findings (suspected TIA) ◆
  - 400 Suspected subarachnoid hemorrhage (SAH) ◆
  - 500 Headache
  - 600 Seizure
  - 700 Head trauma ◆
  - 800 CNS infection
  - 900 Follow-up of intracranial abscess
  - 1000 Follow-up of primary brain tumor
  - 1100 CNS evaluation for brain metastases
  - 1200 Follow-up of AVM and MRI not feasible
  - 1300 Post intracranial procedure/craniotomy/craniectomy
  - 1400 Follow-up post CNS shunt placement
  - 1500 Suspected CNS involvement with systemic disease
  - 1600 Acoustic neuroma/cerebellar pontine angle tumor
  - 1700 Nonacute onset mental status changes/dementia
  - 1800 Suspected cerebral venous thrombosis
  - 1900 Hydrocephalus
  - 2000 Suspected subdural hematoma (SDH)
  - 2100 Follow-up of subdural hematoma (SDH)
- 
- 100 Acute onset persistent neurologic Sx/findings (suspected stroke/CVA) [Both] ◆ <sup>(2\*RIN, 3, 4)</sup>
  - 110 Sx/findings [One]
    - 111 Sensory deficit <sup>(5)</sup>
    - 112 Motor deficit <sup>(6, 7)</sup>
    - 113 Language deficit <sup>(8)</sup>
    - 114 Cognitive dysfunction of unknown etiology <sup>(9, 10)</sup>
    - 115 Visual impairment <sup>(11)</sup>
    - 116 Altered level of consciousness <sup>(12)</sup>
    - 117 Vertigo with headache/central nystagmus <sup>(13, 14, 15, 16)</sup>
  - 120 Symptom onset [One] <sup>(17)</sup>

InterQual® criteria are intended solely for use as screening guidelines with respect to the medical appropriateness of healthcare services and not for final clinical or payment determination concerning the type or level of medical care provided, or proposed to be provided, to the patient.

The Clinical Content is confidential and proprietary information and is being provided to you solely as it pertains to the information requested. Under copyright law, the Clinical Content may not be copied, distributed or otherwise reproduced. Use permitted by and subject to license with McKesson Corporation and/or one of its subsidiaries.

InterQual® copyright © 2011 and CareEnhance® Review Manager copyright © 2011 McKesson Corporation and/or one of its subsidiaries. All Rights Reserved.

May contain CPT® codes. CPT only © 2010 American Medical Association. All Rights Reserved.

Licensed for use exclusively by Royal Health Care.

- 121 < 24 hrs
- 122 ≥ 24 hrs and MRI not feasible<sup>(18, 19)</sup>

## 200 Follow-up study post stroke/CVA [One]

- 210 Anticoagulation planned<sup>(20)</sup>
- 220 New/worsening CNS Sx/findings ♦<sup>(21)</sup>

300 New transient neurologic Sx/findings (suspected TIA) [One] ♦<sup>(22, 23, 24, 25)</sup>

- 310 Sensory deficit<sup>(5)</sup>
- 320 Motor deficit<sup>(6, 7)</sup>
- 330 Language deficit<sup>(8)</sup>
- 340 Cognitive dysfunction of unknown etiology<sup>(9, 10)</sup>
- 350 Visual impairment<sup>(11)</sup>
- 360 Vertigo with headache/central nystagmus<sup>(13, 14, 15, 16)</sup>

400 Suspected subarachnoid hemorrhage (SAH) [One] ♦<sup>(26, 27)</sup>

- 410 Abrupt onset severe headache
- 420 Abrupt onset exertional headache
- 430 Warning or "thunderclap" headache by Hx<sup>(28)</sup>
- 440 Headache **with** associated Sx/findings [One]
  - 441 Vomiting
  - 442 Meningismus<sup>(29)</sup>
  - 443 Focal neurologic finding by PE<sup>(30)</sup>
  - 444 Retinal hemorrhage
  - 445 Syncope<sup>(31)</sup>
  - 446 Mental status changes by Hx/PE<sup>(32)</sup>
  - 447 Blood/xanthochromia by LP<sup>(33, 34)</sup>
  - 448 Seizure<sup>(35)</sup>
  - 449 AVM/aneurysm by Hx<sup>(36)</sup>

500 Headache [Both]<sup>(37\*RIN)</sup>

- 510 MRI not feasible<sup>(38)</sup>
- 520 Sx/findings [One]
  - 521 Papilledema by PE<sup>(39)</sup>
  - 522 New headache [One]<sup>(40)</sup>
    - 1 Age ≥ 50 and no Hx of headaches<sup>(41)</sup>
    - 2 Focal neurologic finding by PE<sup>(30)</sup>
    - 3 Headache with syncope by Hx<sup>(31)</sup>
    - 4 Mental status changes by Hx/PE<sup>(32)</sup>
    - 5 Absent venous pulsations by fundoscopic exam<sup>(42)</sup>
    - 6 Headache onset with exertion/Valsalva maneuver by Hx

- 7 Headache causes awakening from sleep by Hx<sup>(43)</sup>
- 8 Headache with nocturnal vomiting by Hx<sup>(44)</sup>
- 523 Chronic headache **[One]**<sup>(45, 46)</sup>
  - 1 Focal neurologic finding by PE<sup>(30)</sup>
  - 2 Headache with syncope by Hx<sup>(31)</sup>
  - 3 Mental status changes by Hx/PE<sup>(32)</sup>
  - 4 Worsening of previously stable chronic headache by Hx<sup>(47)</sup>
- 600 Seizure **[One]**<sup>(48, 49)</sup>
  - 610 New onset seizure and MRI not feasible ♦<sup>(50, 51)</sup>
  - 620 Seizure disorder by Hx **[Both]**<sup>(38)</sup>
    - 621 MRI not feasible
    - 622 Refractory to Rx **[All]**<sup>(52)</sup>
      - 1 Increased seizure activity with therapeutic blood levels of anticonvulsant
      - 2 ≥ 12 wks since initiation of anticonvulsant Rx<sup>(53)</sup>
      - 3 No concurrent seizure-provoking medication<sup>(54)</sup>
- 700 Head trauma **[One]** ♦<sup>(55)</sup>
  - 710 Retrograde/anterograde amnesia<sup>(56, 57)</sup>
  - 720 LOC by Hx/PE
  - 730 Mental status changes by Hx/PE<sup>(32)</sup>
  - 740 Vomiting<sup>(58)</sup>
  - 750 Focal neurologic finding by PE<sup>(30)</sup>
  - 760 Headache by Hx
  - 770 Seizure by Hx/PE
  - 780 Coagulopathy by Hx
  - 790 Skull fracture by PE/x-ray
- 800 CNS infection **[One]**<sup>(59)</sup>
  - 810 Suspected infection in immunocompetent host **[All]** ♦<sup>(60)</sup>
    - 811 MRI not feasible<sup>(38)</sup>
    - 812 New/worsening CNS Sx/findings **[One]**<sup>(61)</sup>
      - 1 Focal neurologic finding by PE<sup>(30)</sup>
      - 2 Headache by Hx
      - 3 Photophobia<sup>(62)</sup>
      - 4 Meningismus<sup>(29, 63)</sup>
      - 5 Mental status changes by Hx/PE<sup>(32)</sup>
      - 6 Seizure by Hx/PE
    - 813 Associated findings **[One]**<sup>(61)</sup>
      - 1 Temperature > 100.4 F(38.0 C)
      - 2 WBC > 12,000/cu.mm( $12 \times 10^9/L$ )

- 820 Suspected infection in immunocompromised host **[Both]** ♦<sup>(64, 65)</sup>
- 821 MRI not feasible<sup>(38)</sup>
- 822 Sx/findings **[One]**
- 1 Focal neurologic finding by PE<sup>(30)</sup>
  - 2 Atypical headache by Hx<sup>(66)</sup>
  - 3 Mental status changes by Hx/PE<sup>(32)</sup>
  - 4 Seizure by Hx/PE
- 830 Follow-up assessment and MRI not feasible/prior CT<sup>(38, 67, 68)</sup>
- 900 Follow-up of intracranial abscess **[One]**<sup>(69, 70)</sup>
- 910 New/worsening CNS Sx/findings **[One]** ♦
- 911 Focal neurologic finding by PE<sup>(30)</sup>
  - 912 Vomiting
  - 913 Headache by Hx
  - 914 Mental status changes by Hx/PE<sup>(32)</sup>
  - 915 Seizure by Hx/PE
- 920 Follow-up assessment during Rx<sup>(71)</sup>
- 930 Follow-up assessment after Rx completed
- 1000 Follow-up of primary brain tumor **[One]**<sup>(72\*RIN, 73, 74)</sup>
- 1010 New/worsening CNS Sx/findings ♦
- 1020 Periodic assessment<sup>(75)</sup>
- 1100 CNS evaluation for brain metastases **[One]**<sup>(76\*MDR)</sup>
- 1110 Baseline scan as part of staging **[One]**
- 1111 Sarcoma
  - 1112 Melanoma<sup>(77, 78)</sup>
  - 1113 Small cell lung cancer<sup>(79)</sup>
- 1120 Baseline scan positive **[One]**<sup>(80)</sup>
- 1121 Periodic assessment during chemotherapy/radiation Rx<sup>(81)</sup>
  - 1122 Restaging after chemotherapy/radiation Rx completed
- 1130 New/worsening CNS Sx/findings **[One]** ♦<sup>(82)</sup>
- 1131 Known cancer elsewhere
  - 1132 Known brain metastasis by prior CT/MRI
- 1200 Follow-up of AVM and MRI not feasible<sup>(36, 38, 83\*RIN, 84, 85)</sup>
- 1300 Post intracranial procedure/craniotomy/craniectomy **[One]**<sup>(86)</sup>
- 1310 New/worsening CNS Sx/findings ♦
- 1320 Follow-up assessment<sup>(87)</sup>

- 1400 Follow-up post CNS shunt placement **[One]**  
 1410 New/worsening CNS Sx/findings ♦<sup>(88)</sup>  
 1420 Periodic assessment<sup>(89)</sup>
- 1500 Suspected CNS involvement with systemic disease **[One]**  
 1510 Systemic lupus erythematosus (SLE)/vasculitis and MRI not feasible<sup>(38, 90, 91)</sup>  
 1520 HIV<sup>(86)</sup>  
 1530 Sarcoidosis and MRI not feasible<sup>(38, 92)</sup>
- 1600 Acoustic neuroma/cerebellar pontine angle tumor **[Both]**<sup>(93, 94)</sup>  
 1610 MRI not feasible<sup>(19)</sup>  
 1620 Findings **[One]**<sup>(95)</sup>  
 1621 Suspected acoustic neuroma/cerebellar pontine angle tumor **[Both]**  
 -1 Unilateral hearing loss/tinnitus with ear normal by PE<sup>(96)</sup>  
 -2 Findings **[One]**  
 A) Asymmetric neural hearing loss by audiometry<sup>(97)</sup>  
 B) Abnormal acoustic reflex testing<sup>(98)</sup>  
 C) Roll-over by phonetically balanced word testing<sup>(98)</sup>  
 1622 Follow-up known acoustic neuroma **[One]**  
 -1 6 mos from diagnosis/annual follow-up<sup>(99)</sup>  
 -2 Post radiosurgery/surgical excision<sup>(100)</sup>
- 1700 Nonacute onset mental status changes/dementia **[All]**<sup>(101, 102, 103)</sup>  
 1710 MRI not feasible<sup>(38)</sup>  
 1720 Sx/findings **[One]**<sup>(104)</sup>  
 1721 Memory loss by Hx/PE<sup>(105)</sup>  
 1722 Confusion/disorientation by Hx/PE<sup>(106)</sup>  
 1723 Behavioral disturbance by Hx/PE<sup>(107)</sup>  
 1724 Deterioration in intellectual function by Hx/PE  
 1730 Depression screening completed<sup>(108)</sup>  
 1740 Lab results nondiagnostic for etiology of mental status change **[All]**  
 1741 Na  $\geq$  128 mEq/L(128 mmol/L)  
 1742 Glucose  $\geq$  60 and  $\leq$  400 mg/dL(3.33 and  $<$  22.20 mmol/L)  
 1743 BUN  $\leq$  80 mg/dL(28.6 mmol/L)  
 1744 Ca  $\leq$  11 mg/dL(2.75 mmol/L)  
 1745 TSH normal<sup>(109)</sup>  
 1746 LFTs/ammonia normal<sup>(110)</sup>  
 1747 B<sub>12</sub> normal  
 1748 RPR negative/not indicated  
 1750 Urine drug/toxicology screen **[One]**<sup>(111)</sup>

- 1751 Negative
- 1752 Not indicated

- 1800 Suspected cerebral venous thrombosis **[All]** <sup>(112, 113)</sup>
  - 1810 MRI not feasible <sup>(19)</sup>
  - 1820 Headache **with** associated Sx/findings **[One]**
    - 1821 Papilledema by PE <sup>(39)</sup>
    - 1822 Focal neurologic finding by PE <sup>(30)</sup>
    - 1823 Mental status changes by Hx/PE <sup>(32)</sup>
    - 1824 Seizure by Hx/PE
  - 1830 Finding **[One]**
    - 1831 Hypercoagulable state <sup>(114)</sup>
    - 1832 Skull fracture over dural sinus
    - 1833 Calvarial mass <sup>(115)</sup>
    - 1834 Infection **[One]**
      - 1 Rhinosinusitis
      - 2 Otitis media
- 1900 Hydrocephalus **[One]**
  - 1910 Suspected normal pressure hydrocephalus **[Two]** <sup>(116, 117, 118)</sup>
    - 1911 Urinary incontinence
    - 1912 Apraxic gait <sup>(119)</sup>
    - 1913 New onset dementia
  - 1920 Normal pressure hydrocephalus by Hx with new/worsening CNS Sx/findings **♦** <sup>(120)</sup>
  - 1930 Suspected obstructive hydrocephalus **[Both]** <sup>(121)</sup>
    - 1931 Sx/findings **[One]**
      - 1 Headache by Hx
      - 2 Mental status changes by Hx/PE <sup>(32)</sup>
      - 3 Papilledema by PE <sup>(39)</sup>
      - 4 Impaired coordination/ataxia by PE <sup>(122, 123)</sup>
      - 5 Focal neurologic finding by PE <sup>(30)</sup>
      - 6 Seizure by Hx/PE
    - 1932 Risk factor **[One]**
      - 1 AVM/aneurysm by Hx <sup>(36)</sup>
      - 2 SAH/intraventricular hemorrhage by Hx
      - 3 Meningitis
      - 4 Hydrocephalus by Hx
- 2000 Suspected subdural hematoma (SDH) **[Both]** <sup>(124, 125)</sup>
  - 2010 Sx/findings **[One]**
  - 2011 LOC by Hx/PE

- 2012 Mental status changes by Hx/PE<sup>(32)</sup>
- 2013 Bradyphrenia/apathy by Hx/PE<sup>(126)</sup>
- 2014 Focal neurologic finding by PE<sup>(30)</sup>
- 2015 New onset/worsening headache **with** associated Sx/findings [**One**]
  - 1 Persistent vomiting by Hx
  - 2 Pupillary changes<sup>(127)</sup>
- 2016 Seizure by Hx/PE
- 2017 Syncope by Hx<sup>(31)</sup>
- 2018 Skull fracture by PE/x-ray
- 2020 Risk factor [**One**]
  - 2021 Alcohol abuse by Hx
  - 2022 Head trauma by Hx/PE
  - 2023 Anticoagulation Rx<sup>(128)</sup>
  - 2024 Coagulopathy
  - 2025 Age  $\geq$  65<sup>(129)</sup>
  - 2026 CSF shunt by Hx<sup>(130)</sup>
- 2100 Follow-up of subdural hematoma (SDH)<sup>(124, 131)</sup>

## Notes

**(1)**

CT and MRI each have relative advantages and disadvantages. CT, which tends to be better tolerated by patients, has the advantages of a shorter study time, better sensitivity for detecting acute hemorrhage, and excellent visualization of bony structures with less degradation of image quality by motion artifact. CT is often the preferred modality in rapidly evolving neurologic conditions (e.g., SAH, ICH) because it is widely available and may be performed easily in the setting of life support equipment. CT, however, poses the disadvantage of patient radiation exposure which carries an increased long-term risk of cancer. MRI tends to be more sensitive in detecting lesions in the brain, as well as assessment of cerebral ischemia. In acute stroke imaging, both CT and MRI are used to rapidly obtain the necessary anatomical, vascular, and functional information (Adam and Dixon, Grainger & Allison's Diagnostic Radiology: A Textbook of Medical Imaging 5th ed. 2008, 1936 p.).

**(2)-RIN:**

**MRA of the brain may be performed following a stroke to determine etiology as well as appropriateness and timing of treatment. If MRA or CTA of the brain is requested, see the appropriate indication in the "Computed Tomographic Angiogram (CTA), Brain/Magnetic Resonance Angiogram (MRA), Brain" criteria subset.**

**(3)**

The clinical presentation of stroke is typically an abrupt onset of focal neurological signs and symptoms corresponding to a given cerebrovascular territory. History and physical examination remain the pillars of diagnosing stroke.

**(4)**

The primary goals of acute stroke imaging are to distinguish ischemic stroke from intracerebral hemorrhage, to select ischemic stroke patients for reperfusion therapies, and to exclude conditions that mimic acute cerebral ischemia (Adams et al., Stroke 2007; 38(5): 1655-1711). Both CT and MRI may be used to evaluate acute neurologic changes, however, CT is more readily available. CT has the advantage of a shorter study time, assists in discriminating nonvascular causes of neurologic symptoms (e.g., brain tumor), and distinguishes acute ischemic from hemorrhagic stroke. MRI is valuable in acute stroke patients with unusual presentations, stroke varieties, or when a stroke mimic is suspected but not clearly identified on CT. Newer MRI techniques, such as diffusion weighted imaging (DWI), have increased sensitivity for detecting the presence, size, location, and extent of ischemia (European Stroke Organisation (ESO) Executive Committee, Cerebrovasc Dis 2008; 25(5): 457-507; The National Collaborating Centre for Chronic Conditions, National clinical guideline for diagnosis and initial management of acute stroke and transient ischaemic attack. 2008 [cited 2010 April 3]; Adams et al., Stroke 2007; 38(5): 1655-1711; Kidwell et al., JAMA 2004, 292: 1823-30).

**(5)**

Sensory deficits commonly seen in stroke or TIA include hemianesthesia, single limb anesthesia, facial hemianesthesia or hypesthesia, and contralateral neglect (a neglect of the side opposite to the brain insult).

**(6)**

Motor deficits include motor weakness or paralysis (hemiparesis, quadriplegia, single limb involvement, or unilateral facial weakness), impaired coordination or ataxia, or dysphagia.

**(7)**

Motor weakness occurring with a stroke or TIA tends to be focal (e.g., injury to a particular area of the brain results in a specific deficit).

**(8)**

Language deficits most commonly present as aphasia or dysarthria.

**(9)**

Cognitive dysfunction may present as memory loss, confusion, disorientation, or behavioral changes.

**(10)**

Patients presenting with an acute onset of cognitive dysfunction should undergo imaging to search for potentially reversible structural causes of the mental status change, most notably subdural hematoma or acute hemorrhage (Christensen, Am J Emerg Med 2004; 22(3): 228-229). Acute cognitive changes are more likely the result of a toxic or metabolic disorder rather than structural pathology; however, these patients often cannot provide a clear history, making imaging, along with a metabolic evaluation, an important element of the diagnostic algorithm.

**(11)**

Common visual symptoms include new vision loss, diplopia, visual field impairment, gaze impairment, and amaurosis fugax (transient ipsilateral monocular blindness).

**(12)**

Altered levels of consciousness (e.g., coma, marked lethargy) may be due to a variety of mechanisms (e.g., increased ICP, infarct involving arousal systems).

**(13)-DEF:**

Vertigo is a sensation of motion or spinning. Vertigo may be caused by disorders of CN VIII, the inner ear, the brainstem, or the cerebellum.

**(14)-DEF:**

Nystagmus is a form of involuntary eye movement. It is characterized by slow movement in one direction and a rapid corrective movement in the other direction. The direction of nystagmus has been traditionally defined as the direction of the rapid corrective component. It can be vertical, horizontal or rotatory.

**(15)**

Vertigo is very common and, in and of itself, is not an indication for CT or MRI. However, the abrupt onset of vertigo associated with neurologic symptoms (e.g., impaired coordination, ataxia, diplopia, dysphagia, dysarthria, motor or sensory deficits) should raise concerns about intracranial hemorrhage, posterior fossa infarct, or TIA (Kerber, *Semin Neurol* 2009; 29(5): 482-490; Yew and Cheng, *Am Fam Physician* 2009; 80(1): 33-40).

**(16)**

Although headaches are common in adults and often benign in nature, headaches associated with vertigo can be the initial symptom of a life-threatening event such as a brainstem or cerebellar stroke. Imaging is warranted for patients presenting with a sudden, severe headache or a progressively worsening headache associated with the acute onset of vertigo.

**(17)**

The exact time of symptom onset is critical for determining the appropriate imaging study to obtain and the eligibility for thrombolysis (Gorelick and Ruland, *Dis Mon* 2010; 56(2): 39-100; Yew and Cheng, *Am Fam Physician* 2009; 80(1): 33-40). Patients admitted within 3 hours of the symptom onset of stroke may be candidates for intravenous tPA based on the National Institute of Neurologic Disorders and Stroke (NINDS) trial (Chuang et al., *Am J Emerg Med* 2003; 21(3): 167-172; NINDS rt-PA Stroke Study Group, *N Engl J Med* 1995; 333(24): 1581-1587). The European Cooperative Acute Stroke Study (ECASS III) trial demonstrated clinical efficacy if treatment was instituted up to 4.5 hours after the onset of symptoms. The American Heart Association Stroke Council has, therefore, expanded the treatment window for acute ischemic stroke to 4.5 hours based on the results of the ECASS III trial (Bluhmki et al., *Lancet Neurol* 2009; 8(12): 1095-1102; Del Zoppo et al., *Stroke* 2009, 40: 2945-8; Hacke et al., *N Engl J Med* 2008; 359(13): 1317-1329).

**(18)**

MRI is the preferred imaging modality for evaluating neurologic deficits that have been present  $\geq$  24 hours. MRI detects "older" blood and more clearly demonstrates an infarction in this timeframe.

**(19)**

MRI is not feasible if it is not easily available or if the patient cannot tolerate the MRI study.

**(20)**

Depending on the clinical circumstances, patients who are not candidates for thrombolysis at presentation (e.g., uncontrolled HTN) may be candidates for anticoagulation. In this setting, imaging should be performed to help estimate infarct size, as well as to exclude brain hemorrhage. MRI is the preferred imaging, but CT may also be used (Krishnan et al., *J Thromb Thrombolysis* 2010; 29(3): 368-377; Albers et al., *Chest* 2008; 133(6 Suppl): 630S-669S; Adams et al., *Stroke* 2007; 38(5): 1655-1711).

**(21)**

In patients with new or worsening CNS symptoms or findings, CT or MRI may be used.

**(22)-DEF:**

Transient ischemic attack (TIA) is defined as a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute brain tissue infarction. Clinical symptoms generally last for less than one hour.

**(23)**

TIA and stroke are both serious conditions that may cause permanent injury to the brain or lead to disability or death. Early treatment with thrombolytics, anticoagulation, antiplatelet therapy, or surgery can halt or reverse permanent brain damage.

**(24)**

Whether to perform CT or MRI in this setting is a matter of clinical judgment. Both studies can be used to screen for diseases that mimic TIA (e.g., tumor, subdural hematoma). MRI is the preferred study for suspected TIA, as it may detect small lacunar infarcts not well seen on CT and identify new or preexisting ischemic lesions. Because patients with TIA are at a higher risk for recurrent ischemic events, carotid imaging (e.g., US, MRA, CTA) may be warranted to identify an underlying cause (Easton et al., *Stroke* 2009; 40(6): 2276-2293; European Stroke Organisation (ESO) Executive Committee, *Cerebrovasc Dis* 2008; 25(5): 457-507; The National Collaborating Centre for Chronic Conditions, National clinical guideline for diagnosis and initial management of acute stroke and transient ischaemic attack. 2008 [cited 2010 April 3]).

**(25)**

Virtually any transient focal neurologic symptom may reflect a TIA. Some of the more common presentations include weakness of an extremity, localized sensory disturbance, unilateral visual loss, and communication difficulty. Although the acute onset of cognitive dysfunction can occur with a TIA, it is uncommon for patients to present with transient memory loss or confusion without other neurologic symptoms.

**(26)**

SAH due to aneurysm rupture occurs in 25,000 to 30,000 people in the U.S. annually with mortality approaching 45% (Bederson et al., *Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association*. 2009 [cited 40 3]). Usually asymptomatic until they rupture, intracranial aneurysms are the cause of approximately 85% of SAH. Other causes include trauma, AVMs, dural sinus thrombosis, arterial dissection, bleeding diseases, and drugs (Ferro et al., *J Neurol* 2008; 255(4): 465-479; van der Schaaf et al., *Cochrane Database Syst Rev* 2005; (4): CD003085). There is an increased risk for SAH in first degree relatives of patients with a history of SAH (Bederson et al., *Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association*. 2009 [cited 40 3]; Manno, *Neurol Clin* 2004; 22(2): 347-366). The typical presentation is a severe, sudden headache associated with nausea, vomiting, stiff neck, focal neurological deficits, and sometimes loss of consciousness. Some patients present with only mild symptoms, which can lead to a delayed diagnosis or misdiagnosis. The most immediate risks of SAH are recurrent hemorrhage, vasospasm, and cerebral ischemia (van der Schaaf et al., *Cochrane Database Syst Rev* 2005; (4): CD003085).

**(27)**

SAH is suspected when a patient presents with a sudden onset of severe headache, classically described as the "worst headache of my life." CT is the preferred modality to look for acute hemorrhage (Bederson et al., *Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association*. 2009 [cited 40 3]; Brisman et al., *N Engl J Med* 2006; 355(9): 928-939; Suarez et al., *N Engl J Med* 2006; 354(4): 387-396). Conventional MRI is relatively insensitive for acute hemorrhage and is not recommended in this setting. Advanced MRI techniques such as proton-density-weighted images or fluid attenuated inversion recovery images have improved the diagnosis of acute SAH; limitations such as routine availability and longer study time limit practical use in the emergency setting (Bederson et al., *Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association*. 2009 [cited 40 3]). If the CT is negative and a high suspicion for SAH remains, an LP to assess for blood in the CSF should be considered because smaller hemorrhages may not be detected by imaging studies performed acutely (Perry et al., *Ann Emerg Med* 2008; 51(6): 707-713).

**(28)**

Between 20% and 50% of patients with documented SAH report a distinct, severe headache in the days or weeks before they present for medical treatment. This warning or "thunderclap" headache classically develops in seconds, achieves maximal intensity within minutes, and may last hours to days (Bederson et al., *Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association*. 2009 [cited 40 3]; Ferro et al., *J Neurol* 2008; 255(4): 465-479; Manno, *Neurol Clin* 2004; 22(2): 347-366).

**(29)-DEF:**

Meningismus is a symptom complex associated with meningeal irritation, such as neck stiffness or a positive Kernig's or Brudzinski's sign (stretching of the nerve roots causes neck pain).

**(30)**

Focal neurologic finding refers to a specific deficit that corresponds to a particular area of the brain (e.g., right arm weakness from a left motor cortex insult).

**(31)-DEF:**

Syncopal is the transient loss of consciousness and postural tone caused by diminished cerebral blood flow characterized by rapid onset, short duration, and spontaneous complete recovery.

**(32)**

Mental status changes include confusion, lethargy, disorientation, somnolence, stupor, and coma.

**(33)**

Xanthochromia refers to a yellowish discoloration of the spinal fluid suggestive of past hemorrhage, develops 2 to 12 hours after bleeding, and takes at least 2 weeks to clear. Spectrophotometry of the CSF is the recommended method of analysis and should be done on the final sample of CSF collected (Bederson et al., Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. 2009 [cited 40 3]; Suarez et al., N Engl J Med 2006; 354(4): 387-396).

**(34)**

CT should be the initial diagnostic study performed when SAH is suspected. However, in actual practice, LP may be done when SAH was not an initial consideration.

**(35)**

Seizures may occur in up to 20% of patients after SAH, most commonly in the first 24 hours (Bederson et al., Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. 2009 [cited 40 3]).

**(36)-DEF:**

An arteriovenous malformation (AVM) is a vascular lesion consisting of dilated feeding arteries and a core of tangled vascular loops that terminate in draining veins.

**(37)-RIN:**

**These criteria address headache when there is no specific underlying etiology. If there is concern that the headache may be a sign of a stroke, TIA, or SAH, see indication 100, 300, or 400, respectively.**

**(38)**

MRI is not feasible if it is not readily available or if the patient cannot tolerate the MRI study.

**(39)-DEF:**

Papilledema is swelling of the optic disc, manifested by indistinct margins, hyperemia, venous engorgement, and lack of normal venous pulsations. Papilledema is a sign of increased ICP.

**(40)**

These criteria address a new or not as yet investigated headache. The headache may actually have been present for some time before the patient seeks medical attention. As the incidence of serious intracranial problems is extremely low in patients with a headache and a normal neurologic exam, a selective approach to ordering imaging studies in these patients is appropriate. These criteria define risk factors which are worrisome for intracranial pathology (e.g., tumor, hemorrhage). MRI is generally preferred over CT for the evaluation of headaches. CT is sensitive for identifying SAH or subdural hematoma, but MRI is more sensitive than CT for identifying lesions of the posterior fossa, ischemia, cerebral venous thrombosis, neoplasms, meningeal disease, and cerebral abscess (Edlow et al., Ann Emerg Med 2008; 52(4): 407-436; Karis, AJNR Am J Neuroradiol 2008; 29(6): 1222-1224; Schaefer et al., J Am Coll Radiol 2007; 4(8): 566-569).

**(41)**

Neuroimaging is appropriate for patient's  $\geq 50$  years of age presenting with a new headache. Headache in a patient in this age group who has no previous history of headaches may indicate significant disease (e.g., temporal arteritis, mass) (Edlow et al., Ann Emerg Med 2008; 52(4): 407-436; Karis, AJNR Am J Neuroradiol 2008; 29(6): 1222-1224; Schaefer et al., J Am Coll Radiol 2007; 4(8): 566-569).

**(42)**

Venous pulsations occur normally due to variation in pressure along the retinal vein. Cessation of venous pulsation occurs with a rise in ICP, making this finding a sensitive marker of increased ICP (Jacks and Miller, J Neurol Neurosurg Psychiatry 2003; 74(1): 7-9).

**(43)**

Headaches causing patients to awaken from sleep may be caused by increased ICP.

**(44)**

Nocturnal vomiting may signify an intracranial tumor or may represent increased ICP.

**(45)**

Migraine is the most common type of chronic headache, triggered by factors such as stress, certain foods, hormonal changes, or lack of sleep. Treatment involves sleep, analgesics, and biobehavioral therapies (e.g., diet, relaxation techniques, cognitive therapies). Diagnosis of most patients with chronic headaches (e.g., migraine, tension headache) usually does not require imaging, particularly in the absence of neurologic signs and symptoms (Friedman and Grosberg, *Emerg Med Clin North Am* 2009; 27(1): 71-87; Lewis, *Neurol Clin* 2009; 27(2): 481-501; Pearlman, *Prim Care* 2004; 31(2): 407-415, viii).

**(46)**

Imaging is not generally indicated for patients with chronic headache without other associated neurologic signs and symptoms; it is uncommon to discover any imaging abnormalities in this setting (Jordan, *AJNR Am J Neuroradiol* 2007; 28(9): 1824-1826; McConaghy, *Prim Care* 2007; 34(1): 83-97). For patients with chronic headache and associated neurologic symptoms, imaging may be indicated. MRI is the study of choice due to its enhanced sensitivity in the detection of intracranial pathology (Schaefer et al., *J Am Coll Radiol* 2007; 4(8): 566-569).

**(47)**

Headache patterns of frequency and severity are often cyclical and related to environmental, hormonal, or social factors. Significant worsening of a previously stable headache can indicate new pathology and warrants imaging.

**(48)**

Seizure disorders may be of varying focality and intensity. Status epilepticus is a condition characterized by seizures lasting for at least 30 minutes that are either continuous or rapidly repeating, such that recovery (return to full consciousness) does not occur between attacks. Generalized or grand mal seizures involve the entire brain and are associated with generalized convulsions and LOC. Partial or focal seizures result from epileptiform activity localized to one area of the brain. The particular area that is affected will determine the resulting symptom. Complex partial or focal seizures, formerly referred to as temporal lobe and psychomotor seizures, are characterized by the episodic loss of conscious "awareness," and may begin as a simple partial seizure. Complex partial seizures may subsequently generalize (to involve the entire brain) and cause total loss of consciousness and convulsions.

**(49)**

Seizure with accompanying neurologic findings may suggest an anatomic cause for the seizure (Adams and Knowles, *Am Fam Physician* 2007; 75(9): 1342-1347; Shneker and Fountain, *Dis Mon* 2003; 49(7): 426-478).

**(50)**

Neuroimaging is recommended for the evaluation of patients presenting with a first unprovoked seizure (Krumholz et al., *Neurology* 2007; 69(21): 1996-2007; ACEP Clinical Policies Committee, *Ann Emerg Med* 2004; 43(5): 605-625). MRI is the study of choice due to its enhanced sensitivity, although CT is a reasonable alternative when MRI is not feasible (National Institute for Clinical Excellence (NICE), *The epilepsies. Clinical Guideline 20. 2004, 73*; Shneker and Fountain, *Dis Mon* 2003; 49(7): 426-478).

**(51)**

MRI is not feasible if it is not readily available or if the patient cannot tolerate the MRI study.

**(52)**

Refractory seizures do not require imaging unless a new lesion is suspected (e.g., change in seizure pattern) or management will change based on the results of the scan.

**(53)**

Time is required to adjust medications and assess their results before assuming that the seizures are refractory to treatment.

**(54)**

Prescription medications such as TCAs, antipsychotics, theophylline, and lidocaine can lower the seizure threshold. Attempts should be made to reduce or discontinue all such medications, but the risks and benefits of such an intervention need to be considered for each patient.

Recreational CNS stimulants (e.g., cocaine) can also cause seizures.

**(55)**

After head trauma, CT is the initial imaging procedure of choice to assess for fracture and to exclude intracranial hemorrhage. MRI may be more sensitive in assessing neural injury after the first 24 hours and for detecting small subdural hematomas. With evolving MRI technology, such as magnetic resonance spectroscopy, diffusion-tensor imaging, and magnetization transfer MRI, there may be an increase in future utility of MRI in head trauma imaging (Jagoda et al., *Ann Emerg Med* 2008; 52(6): 714-748; Sigmund et al., *Pediatr Neurol* 2007; 36(4): 217-226; Smits et al., *Radiology* 2007; 245(3):831-838).

**(56)-DEF:**

Retrograde amnesia is having no memory of the events that occurred before the trauma or condition.

**(57)-DEF:**

Anterograde amnesia is having no memory for events that occurred after the trauma or condition.

**(58)**

Vomiting after head trauma may be an early indication of increased ICP.

**(59)**

The superior contrast resolution of MRI makes it a more sensitive imaging tool for evaluating intracerebral abnormalities associated with a variety of complicated CNS infectious processes. Gadolinium contrast improves lesion delineation, localizes regions likely to provide positive biopsy, and identifies active disease. Additional information may be obtained from using diffusion-weighted imaging. In uncomplicated cases, CT may be obtained initially to identify patients at higher risk for herniation with intracranial abnormalities such as hydrocephalus, mass lesions, cerebral edema, and midline brain shift. LP often follows CT in the event the patient is considered low risk for herniation (Fitch et al., *Infect Dis Clin North Am* 2008; 22(1): 33-52, v-vi; Kastrup et al., *NeuroRx* 2005; 2(2): 324-332).

**(60)**

These criteria address CNS infection in the immunocompetent host, where the concern is generally for meningitis or encephalitis.

**(61)**

In the setting of meningitis or encephalitis, an immunocompetent host will usually demonstrate signs of infection such as fever, elevated WBC, neck stiffness, or neurologic signs. Imaging in this context is helpful to rule out other possible etiologies that might confound or complicate the diagnosis.

**(62)-DEF:**

Photophobia is abnormal visual intolerance to light.

**(63)**

Meningismus may be seen with any meningeal irritant but should raise the suspicion of infectious meningitis.

**(64)**

Immunocompromised hosts are individuals whose immune system is defective either because of a primary underlying immunodeficiency disorder or because of the administration of medications that suppress the immune response.

**(65)**

Although both CT and MRI are effective imaging tools in patients with AIDS-related disease, MRI is the study of choice. MRI is preferred for tuberculous meningitis, common in patients with AIDS, because it can reveal small infarctions, granulomas, and inflammation of the ventricles. MRI is also preferred in suspected fungal infections due to its superior resolution and sensitivity to tissue edema (Fitch et al., *Infect Dis Clin North Am* 2008; 22(1): 33-52, v-vi; Kastrup et al., *NeuroRx* 2005; 2(2): 324-332).

**(66)**

These criteria address headaches of concern to the provider and patient because of features that are atypical for the patient. The headache may be atypical because it is unusually severe, long-lasting, or because it has new or differing characteristics from prior headaches.

**(67)**

Follow-up assessment is not necessary more frequently than every 7 to 10 days if the patient is stable or improving.

**(68)**

It is generally best to perform the same study serially, as this allows direct comparison of studies.

**(69)**

Abscesses involving the CNS are uncommon. They sometimes result from direct trauma or neurosurgery, but may be caused by meningitis, rhinosinusitis, mastoiditis, and other extra-cranial sources (Ziai and Lewin, *Neurol Clin* 2008; 26(2): 427-468, viii).

**(70)**

Whether to perform a CT or MRI in this setting is a matter of clinical judgment. While MRI provides greater detail, CT is often sufficient for follow-up studies. It is generally best to perform the same study serially as this allows direct comparison of studies.

**(71)**

The frequency of assessment is a matter of clinical judgment based upon the size, location, and number of intracranial abscesses. Follow-up is necessary to monitor resolution of the abscess in response to antibiotic therapy. If there is no progress, surgical drainage

may be necessary.

**(72)-RIN:**

**These criteria address a previously diagnosed brain tumor. For symptomatology which makes one suspect a new brain lesion, see the appropriate indication within this criteria subset.**

**(73)**

The most common primary brain tumors in adults are gliomas and meningiomas, with gliomas accounting for more than 80% of primary brain tumors (Chandana et al., Am Fam Physician 2008; 77(10): 1423-1430; Grant, J Neurol Neurosurg Psychiatry 2004; 75 Suppl 2: ii18-23).

**(74)**

Whether to perform a CT or MRI in this setting is a matter of clinical judgment. MRI is preferred for imaging all types of brain tumors because of its high sensitivity, its ability to identify tumor sites near bone, its sensitivity to tissue edema, and its capability of accurately delineating tumors and their relationship to normal structures.

**(75)**

Periodic assessment is performed to evaluate response to therapy.

**(76)-MDR:**

**There may be instances other than sarcoma, melanoma, or small cell lung cancer for which initial staging may include CNS imaging. Although this may be reasonable depending on the grade, extent, and location of the primary tumor, these cases require secondary medical review.**

**(77)-DEF:**

Melanoma is a malignant tumor of melanocytes, which are found predominantly in skin.

**(78)**

The incidence of melanoma is increasing more rapidly than any other malignancies, at a rate of > 4% per year (Jemal et al., CA Cancer J Clin 2008; 58(2): 71-96). Although the precise pathogenic etiology of melanoma is unknown, risk factors such as association with intermittent, intense sun exposure, older age, and exposure to pesticides have been identified (MacKie et al., Ann Oncol 2009; 20 Suppl 6: vi1-7). A family history of melanoma increases a patient's risk for developing melanoma.

**(79)**

CT or MRI may be performed as part of initial staging in patients with known small cell carcinoma of the lung to facilitate decision-making regarding therapy. Patients with documented CNS involvement at presentation are not candidates for prophylactic radiation therapy. Also, conventional chemotherapy is ineffective for treatment of small cell carcinoma of the lung once it has metastasized to the brain because the CNS is protected by the blood-brain barrier.

**(80)**

The interval for periodic assessment in stable patients is a matter of clinical judgment. Studies are generally performed no more frequently than every two cycles of chemotherapy.

**(81)**

The assessment is generally not necessary more frequently than every two cycles of chemotherapy.

**(82)**

Although any malignancy can metastasize, breast and lung cancer are the two most common primary sites of cancer in patients presenting with brain metastases (American College of Radiology (ACR), ACR Appropriateness Criteria for Pre-Irradiation Evaluation and Management of Brain Metastasis. 2005.). Patients with documented malignancy that develop new CNS symptoms or findings should undergo imaging to exclude the possibility of brain metastases.

**(83)-RIN:**

**This indication covers follow-up of a known AVM. For new symptoms in a patient with a known AVM (e.g., suspected rupture and SAH), see indication 400 within this criteria subset.**

**(84)**

AVMs typically present between the ages of 20 and 40. Ruptured cerebral AVMs account for 1% to 2% of all strokes and 9% of cases of SAH. The most common presentation of an AVM is intracranial hemorrhage, with approximately 50% of patients presenting with hemorrhage (Bashir et al., Neurol Clin 2008; 26(4): 1099-1127, x; Choi and Gershenwald, Surg Oncol Clin N Am 2007; 16(2): 403-430). Each hemorrhagic event is associated with significant morbidity and 30% mortality (Cockcroft, Stroke 2007; 38(12): 3310-3311; Al-Shahi and Warlow, Cochrane Database Syst Rev 2006; (1): CD003436; Choi and Mohr, Lancet Neurol 2005; 4(5): 299-308). The risk of recurrent hemorrhage is estimated to be 25% within the first year following the initial hemorrhage (Khatri et al.,

Neurol Clin 2009; 27(1): 109-137, viii).

**(85)**

Follow-up imaging is generally not indicated in stable AVM without changes in symptoms or treatment plan.

**(86)**

Whether to perform CT or MRI in this setting is a matter of clinical judgment.

**(87)**

It may be reasonable to obtain imaging studies in the immediate postoperative period following an intracranial procedure. These patients are often acutely ill and the determination of neurologic status can be difficult, as it is often complicated by sedating medication or cerebral edema. Clinical judgment may dictate early scanning if the patient fails to progress as expected, even if worrisome focal neurologic signs are absent.

**(88)**

New or worsening CNS symptoms in a patient with a CNS shunt may reflect acute hydrocephalus resulting from shunt malfunction. In this setting, CT is most appropriate as it is fast and will clearly demonstrate enlargement of the ventricles.

**(89)**

Periodic imaging may be indicated for patients with a CNS shunt to determine ventricular size and assess response to treatment.

**(90)**

Symptoms and findings of CNS involvement by SLE or vasculitis are quite varied but typically include headache, mental status changes, seizure, or stroke. Focal or nonspecific neurologic findings may also accompany HIV, without concomitant opportunistic CNS infection. These diseases have characteristic imaging findings that aid in diagnosis and thereby guide therapy.

**(91)**

MRI is more sensitive than CT for detection of intracranial lesions caused by vasculitis.

**(92)**

Neurological involvement in sarcoidosis is seen in approximately 5% to 10% of cases; approximately half of these cases involve the CNS. Presenting signs and symptoms of CNS involvement include mental status changes (e.g., somnolence), seizures, and cranial nerve palsies. CT or MRI imaging may diagnose neurosarcoidosis but gadolinium-enhanced MRI is the preferred imaging study to evaluate the brain parenchyma, the spinal cord, and the meninges (Lower and Weiss, Clin Chest Med 2008; 29(3): 475-492, ix).

**(93)**

An acoustic neuroma is a benign neoplasm of the Schwann cells of the vestibular nerve (CN VIII). Although vertigo is the most common presenting symptom, it is often associated with tinnitus or unilateral hearing loss (Chawla and Olshaker, Med Clin North Am 2006; 90(2): 291-304).

**(94)**

MRI with gadolinium contrast is the gold standard imaging tool. It provides excellent soft tissue visualization, is the most sensitive for detecting acoustic neuromas, and will show all detectable neuromas (Curtin and Hirsch, Neurosurg Clin N Am 2008; 19(2): 175-205, v).

**(95)**

The brainstem auditory evoked response is known as BAER or ABER and is almost always abnormal with an acoustic neuroma. Auditory brainstem response is less sensitive to small (< 2 cm) neuromas and the test is often nondiagnostic in patients with profound hearing loss (Cheng et al., J Otolaryngol 2003; 32(6): 394-399). This test is an appropriate screening in patients with limited symptoms (e.g., isolated vertigo, symmetric hearing loss, unilateral hearing loss explained by history) and therefore at low risk for acoustic neuroma.

**(96)-DEF:**

Tinnitus describes a subjective sense of ringing, whistling, booming, or buzzing within the ear.

**(97)**

A 15 to 20 db difference is common, but there is no absolute threshold.

**(98)**

The abnormal acoustic reflex and roll-over phenomenon are audiometric tests.

**(99)**

Routine follow-up is indicated for patients who have not undergone radiotherapy or surgical excision. Initial follow-up 6 mos after diagnosis, then annually is appropriate if tumor growth is  $\geq 2$  mm/year (Doherty and Friedman, Curr Opin Otolaryngol Head Neck

Surg 2006; 14(5): 305-313).

**(100)**

Residual tumor is not uncommon following surgical excision or radiotherapy for acoustic neuroma (Curtin and Hirsch, Neurosurg Clin N Am 2008; 19(2): 175-205, v; Wiet et al., Otolaryngol Clin North Am 2006; 39(4): 751-762, vii). Routine follow-up for these patients is recommended to assess for residual tumor growth or recurrence. The frequency of follow-up is a matter of clinical judgment.

**(101)-DEF:**

Dementia is defined as a documented decline in multiple cognitive functions (e.g., memory, language, visuospatial ability) which is severe enough to interfere with daily life.

**(102)**

Chronic mental status changes can have a number of etiologies, including metabolic disturbance, substance dependence, vitamin deficiency, and hereditary disease. Dementia is a specific type of chronic mental status change, without diminished awareness or altered consciousness. Prior to imaging, a thorough metabolic evaluation is indicated to assess for reversible or treatable etiologies. Although treatment of these disorders may not completely reverse cognitive dysfunction, they should be routinely screened for, and if present, treated. Depression and medication side effects also need to be excluded during the evaluation (Holsinger et al., JAMA 2007; 297(21): 2391-2404; National Institute for Health and Clinical Excellence (NICE), Dementia: supporting people with dementia and their carers in health and social care. Clinical guideline 42. 2006, 56 p.; Connelly and James, Int J Geriatr Psychiatry 2006; 21(1): 14-16). Imaging can exclude potentially treatable causes of dementia (e.g., subdural hematoma, brain tumor, normal pressure hydrocephalus) (Gallucci et al., Radiol Clin North Am 2008; 46(4): 799-817, vii; Whitwell and Jack, Neurol Clin 2007; 25(3): 843-857, viii).

**(103)**

The American Academy of Neurology (AAN) and European Federation of Neurological Societies (EFNS) guidelines recommend that either a noncontrast CT or MRI scan be used for the initial evaluation of patients with dementia (Waldemar et al., Eur J Neurol 2007; 14(1): e1-26; Knopman et al., Neurology 2001; 56(9): 1143-1153). MRI is the preferred imaging study, however, as it has increased specificity, improved tissue contrast, and the ability to detect focal temporal lobe abnormalities, subcortical vascular changes, and can identify different patterns of atrophy. CT is primarily used to exclude other conditions that may be amenable to treatment, (e.g. brain tumors, subdural hematomas, hydrocephalus).

**(104)**

Cognitive assessment in patients with mental status changes and suspected dementia should include examination of attention and concentration, orientation, short- and long-term memory, language, and executive functioning. The Mini Mental Status Examination (MMSE) is commonly used, however, there are many alternate cognitive testing instruments available. Formal neuropsychological testing provides valuable information in the cognitive assessment of a patient with suspected dementia (Waldemar et al., Eur J Neurol 2007; 14(1): e1-26; National Institute for Health and Clinical Excellence (NICE), Dementia: supporting people with dementia and their carers in health and social care. Clinical guideline 42. 2006, 56 p.; Connelly and James, Int J Geriatr Psychiatry 2006; 21(1): 14-16). Cognitive testing should include assessing for behavioral and psychological symptoms that are common in dementias and Alzheimer's disease, such as apathy, agitation, and anxiety (Waldemar et al., Eur J Neurol 2007; 14(1): e1-26).

**(105)-DEF:**

Memory loss is the inability to remember people, places, objects, or events from the recent or distant past. In patients with dementia, memory loss is progressive in nature and interferes with IADLs and ADLs.

**(106)**

Confusion is characterized by fluctuating levels of consciousness and attention. Most commonly, confusion has a toxic or metabolic etiology, but imaging may be required to exclude a structural cause.

**(107)**

Behavioral disturbances may reflect frontal lobe dysfunction.

**(108)**

Depression is often under diagnosed, especially in the elderly, and may be mistaken for dementia (and vice versa) as a cause of mental status change.

**(109)**

Hypothyroidism can be associated with impaired memory and psychomotor skills, which may improve after thyroid hormone replacement (Devdhar et al., Endocrinol Metab Clin North Am 2007; 36(3): 595-615, v).

**(110)**

Liver failure can cause hepatic encephalopathy and resultant mental status changes. Serum ammonia is a commonly used marker, which correlates with the severity of this condition; however, there is no absolute value which defines a particular stage of encephalopathy (Munoz, *Med Clin North Am* 2008; 92(4): 795-812, viii). The PCP should consider this diagnostic possibility prior to seeking neurologic consultation.

**(111)**

All medications, including nonprescription drugs and herbal supplements, should be reviewed for potential side effects and interactions. Particular attention should be paid to beta blockers, antihistamines, benzodiazepines, psychotropics, anticholinergics, opiates, and centrally acting antihypertensives.

**(112)**

Cerebral venous thrombosis (CVT) is an occlusion of the cerebral veins and can lead to infarction of the involved cerebral territories. This disorder may present as a slowly progressive process or as an acute neurologic emergency. Risk factors for the development of cerebral venous thrombosis include dehydration, systemic and local infection, head trauma, pregnancy, puerperium, cancer, trauma, and coagulopathies (Stam, *N Engl J Med* 2005; 352(17): 1791-1798). The clinical presentation of CVT is often nonspecific. Common presenting symptoms include recent onset, progressive headache frequently associated with focal neurologic deficits, seizures, and altered consciousness. A syndrome of intracranial hypertension that includes headache and papilledema can account for up to 40% of cases (Poon et al., *AJR Am J Roentgenol* 2007; 189(6 Suppl): S64-75).

**(113)**

Since the clinical presentation may be variable, cerebral venous thrombosis can be difficult to diagnose. Early diagnosis is essential for prompt appropriate treatment and improved patient outcome. Magnetic resonance venography, a component of MRA to evaluate the venous circulation, provides more definitive information when performed in conjunction with MRI. MRI and magnetic resonance venography are appropriate when cerebral venous thrombosis is suspected. CT may be used as an initial screening tool to rule out other acute cerebrovascular disorders. CT venography is emerging as a competing technique for imaging of the cerebral venous system (Poon et al., *AJR Am J Roentgenol* 2007; 189(6 Suppl): S64-75; Khandelwal et al., *AJR Am J Roentgenol* 2006; 187(6): 1637-1643; Stam, *N Engl J Med* 2005; 352(17): 1791-1798).

**(114)**

A hypercoagulable state can develop due to malignancy, sickle cell disease, coagulation disorders (e.g., protein C or S deficiency, antithrombin III deficiency), during pregnancy or the postpartum period, or from the use of oral contraceptives.

**(115)**

A mass arising from the skull (e.g., calvarium) can result in occlusion of the cerebral veins.

**(116)-DEF:**

Normal pressure hydrocephalus is an acquired hydrocephalus involving impaired CSF reabsorption. The pressure of the CSF usually remains within normal range.

**(117)**

The classic triad of symptoms of normal pressure hydrocephalus is urinary incontinence, apraxic gait, and dementia. Gait and balance difficulties often appear before urinary incontinence and cognitive decline (Factora and Luciano, *Clin Geriatr Med* 2006; 22(3): 645-657; Wilson and Williams, *Clin Geriatr Med* 2006; 22(4): 935-951, viii). Sometimes only one or two symptoms are present.

**(118)**

CT or MRI findings, which suggest normal pressure hydrocephalus, include enlarged ventricles with intact cerebral parenchyma; the latter distinguishes this disorder from Alzheimer's disease where cortical atrophy is significant (Gallia et al., *Nat Clin Pract Neurol* 2006; 2(7): 375-381; Wilson and Williams, *Clin Geriatr Med* 2006; 22(4): 935-951, viii).

**(119)-DEF:**

An apraxic gait is slow, shuffling, short-stepped, and broad-based. It results from the inability to preplan proper foot and leg positions, or translate that plan into motor patterns.

**(120)**

In patients with known normal pressure hydrocephalus and new or worsening CNS symptoms or findings, a CSF shunt may be needed to improve symptoms. Imaging is helpful in assessing the size of the ventricles and helping to determine the need for shunt placement.

**(121)**

Obstructive (or tension) hydrocephalus develops when there is obstruction to the flow of CSF, creating an accumulation of fluid in the ventricles and thus increased ICP. It can result from intraventricular bleeding, SAH, tumor, or infection of the brain and spinal cord. Symptoms include headaches, papilledema, temporal lobe seizures, CSF rhinorrhea (the leakage of spinal fluid from the nose), and mental status changes (Goetz, Textbook of clinical neurology, 3rd ed. ed. 2007, xvii, 1364 p.).

**(122)-DEF:**

Ataxia is incoordination or awkwardness in performance of a motor task. The term ataxia is often used to describe gait unsteadiness.

**(123)**

Impaired coordination suggests cerebellar pathology. Inability to perform rapid alternating movements, finger to nose testing, or heel to shin testing are examples of impaired coordination.

**(124)**

Subdural hematomas develop as the result of trauma. In acute cases, there is often a clear history of head trauma with a rapid progression of symptoms that may lead to coma. In chronic cases, the head trauma may have been minor and even forgotten. Symptoms (e.g., slowness in thinking, confusion, apathy, drowsiness) may not become apparent for a period of weeks following the precipitating event (Bullock et al., Neurosurgery 2006; 58(3 Suppl): S16-24; discussion Si-iv; Karnath, Geriatrics 2004; 59(7): 18-23).

**(125)**

CT is the preferred study for the initial evaluation of suspected subdural hematoma (Bullock et al., Neurosurgery 2006; 58(3 Suppl): S16-24; discussion Si-iv). MR imaging is more sensitive than CT in the detection of small subdural hematomas and subdural hematomas that are in the subacute phase (Provenzale, Emerg Radiol 2007; 14(1): 1-12).

**(126)-DEF:**

Bradyphrenia is slowness of thought and information processing.

**(127)**

Pupillary changes include asymmetry and an abnormal reaction to light.

**(128)**

A subdural hematoma may develop gradually after head trauma in patients on anticoagulants. CT scans done shortly after the head trauma may be negative and repeat imaging may be indicated if their clinical signs and symptoms change or worsen.

**(129)**

Advanced age is associated with a greater risk of falls resulting in traumatic injuries, and a greater likelihood of medical conditions which require treatment with anticoagulation therapy. Other factors, including age-related cortical atrophy, increase the risk of chronic subdural hematoma in the elderly. In addition, primarily because of these age-related changes, the clinical presentation of the disease in the elderly varies from the presentation in younger adults. A common clinical presentation in the older patient includes headache, altered mental status, hemiparesis, gait disturbance, and aphasia. Higher rates of mortality in the elderly from chronic subdural hematoma have been attributed to this variation in clinical presentation resulting in a delay in diagnosis (Karnath, Geriatrics 2004; 59(7): 18-23).

**(130)**

A subdural hematoma occurring following CSF shunting for normal pressure hydrocephalus is considered a mechanical failure (Chen and Levy, Neurosurg Clin N Am 2000; 11(3): 399-406).

**(131)**

Serial CT scans are obtained following surgical evacuation of a SDH to assess for reaccumulation of the hematoma or to check for a residual hematoma membrane that prevents re-expansion of the brain (Bullock et al., Neurosurgery 2006; 58(3 Suppl): S16-24; discussion Si-iv). Some acute SDH will resolve spontaneously without the need for surgical intervention. Serial CT scans are obtained to monitor status. Asymptomatic small, chronic SDH are also followed with serial CT scans (Karnath, Geriatrics 2004; 59(7): 18-23).